- December 9, 2025
- Posted by: Josh Knoll
- Category: Infusion Billing Services
Infusion therapy is complex because it balances high drug costs, changing payer rules and complex billing. The the whole balance is shifting fast as we all move into 2026 as the site-neutral payment are rising and reshaping the infusion billing services. It is imperative to understand the critical changes to survive financially well. Let’s know about the potential changes in 2026, how they matter and effective infusion billing services strategies to implement to stay compliant and profitable.
Key changes in infusion billing for 2026
The following are the upcoming changes in your infusion billing services.
1) Rising drug costs and declining reimbursements-
Drug cost inflation is now one of the biggest threats to infusion therapy revenue. Prices for biologics, IVIG, monoclonal antibodies, chemo drugs, and specialty injectables have risen much faster than normal medical inflation, with some doubling in just a few years and this trend isn’t slowing in 2026. Many infusion drugs are reimbursed based on Average Sales Price (ASP), so when acquisition costs rise faster than reimbursement, providers lose money.
Hospitals have managed this better than independent infusion clinics because of 340B pricing and stronger payer leverage, but even they are feeling the pressure. As drug prices climb, the financial risk grows, especially for providers using a buy-and-bill model. A denied or delayed claim can leave tens or even hundreds of thousands of dollars stuck in limbo. One missed or expired prior authorization can wipe out an entire treatment’s revenue. We cannot deny the fact that the demand for infusion care is rising, but profit margins are going south as every billing mistake eats up your overall profitability.
2) Site-neutral payment reform-
For years, infusion reimbursement depended on where treatment happened, with hospitals getting paid more than physician offices or home infusion providers for the same service. Payers argued this was unfair and limited competition You might have already seen that site-neutral payment reform is moving fast, especially for Medicare and Medicare Advantage plans. The goal is simple: pay the same rate no matter where the infusion is delivered. While fair in theory, the impact is big. A lot of hospitals may lose millions in reimbursement, especially when the biologics and oncology infusions are concerned. Your cost control measures can be the key to survival.
Rising drug prices and new site-neutral rules mean that your billing needs to be accurate more than ever. You can expect insurance payers to look closely at coding, modifiers, drug cost reporting, place of service, prior authorization details, and medical necessity. You may face a high-value infusion turning into a denial or take-back due to a single mistake in your billing process which is for costly specialty drugs like Remicade, Stelara, Ocrevus, Humira biosimilars, and oncology biologics.
The rising role of home infusion and alternative sites of care-
A major change happening is the push from payers toward home infusion therapy because it costs less than hospital-based care. With site-neutral rules moving forward, this shift becomes even more attractive. Patients also prefer home infusion because it’s easier, safer, and more personal but home infusion billing is not the same as office-based billing as it involves different rules, supply codes, nursing codes, pump billing, and separate drug reimbursement structures. You need to need to understand billing for Medicare Part B, Medicare Advantage, commercial plans, and new payer carve-outs to enjoy revenue success. The practices that will survive are the ones that adapt and diversify—not the ones that rely on a single care setting.
1) More prior authorization pressure:
Payers will protect themselves by tightening prior authorization requirements due to the skyrocketing drug prices. Crucial changes related to Prior Authorization that you can expect in 2026 :
- Stricter medical necessity reviews
- Expedited expiration timelines
- More step therapy enforcement
- Mandatory biosimilar substitution
- Increased peer-to-peer review requirements
Prior authorization mistakes are already a top cause of lost revenue in infusion, and with drug prices increasing, the financial risk of delays or denials becomes even larger.
Providers will need tighter tracking systems, automated reminders, and revenue cycle teams who specialize in infusion-specific authorization workflows. Manual processes won’t meet 2026 requirements.
Highly precision coding and documentation:
Coding accuracy becomes essential for proper payment and avoiding audits with the progress of site-neutral reforms. Documentation, medical necessity notes, dosage details, and infusion time logs must be complete and consistent. In 2026, auditors will pay closer attention to time-based infusion billing and chemotherapy coding. Coders must understand drug wastage rules, time-based code selection, therapy hierarchy, modifiers, and the difference between billing biosimilars and originator biologics. Even one small coding mistake can lead to lost revenue, delays, or expensive post-payment audits.
Contract negotiation and payer communication will matter more:
Payer negotiations are no longer just an administrative task, it is a strategic approach as well with the site-neutral payment and increasing drug prices. You need stronger cost transparency, better contract terms and better billing workflow to safeguard your revenue.
2026 will be the year when many infusion providers realize they can no longer afford to let payers dictate terms without strategy and analytics support.
Those who walk into contract negotiations with real claims data, documented denial trends, and drug acquisition cost analysis will have the upper hand.
Infusion therapy isn’t slowing down. In fact, demand is increasing due to rising rates of autoimmune disease, cancer, chronic inflammatory conditions, and biologic prescription growth.
But the business model behind infusion billing is being rewritten. The industry is entering an era where operational efficiency, compliant billing workflows, revenue integrity oversight, and predictive analytics are the competitive advantages—not optional extras.
To succeed through 2026 and beyond, infusion providers must:
- Adapt to site-neutral reimbursement models
- Strengthen billing accuracy and documentation
- Improve prior authorization workflows
- Prepare for payer-driven channel shift to home infusion
- Leverage data and billing intelligence to guide decisions
The providers who respond early will protect margins and grow market share. Those who wait may struggle to survive.
Unfortunately, most infusion practices lack a dedicated and experienced team that can handle the end-to-end infusion billing services and stay on top of all the real-time and potential billing changes. Are you also one of them? You can simply outsource your revenue cycle management to SunKnowledge Inc.
SunKnowledge: Your trusted infusion billing services provider
We stand out because we have decades of experience in healthcare revenue cycle management and offer complete support for infusion providers across the U.S. We handle everything from eligibility checks and prior authorization to claim submission, payment posting, and denial management. We are fully HIPAA compliant, offer end-to-end billing support, have certified coders, provide real-time reporting, and deliver unmatched cost savings with rates as low as $7/hour.
Our highly proficient RCM experts know what it takes to ensure up to 80% savings compared to your in-house team. Infusion billing is complex and time-consuming, and coding rules, documentation requirements, and payer policies make it hard for many practices to stay compliant and we can come as the perfect help. We’re one call away reach out to learn more..